A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versusPlacebo in Subjects with High Risk Invasive Urothelial Carcinoma
The purpose of this study is to compare any good and bad effects of using nivolumab (study drug) in urothelial carcinoma. The study drug could prevent your cancer from returning but it could also cause side effects. This study will allow the researchers to know how well the drug works.
Urothelial carcinoma which includes cancers of the urinary bladder, ureter & parts of the kidney.
1) At least 18 years of age
2) Confirmed cases of urothelial carcinoma
3) Needs to have your cancer removed by surgery within the last 3 months and be currently disease free
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will receive study drug for up to a period of one year. There will be follow-up examinations (without study drug) for a maximum of five years.
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com